BACKGROUND: Growth faltering during infancy is a characteristic of life in developing countries. Previous studies have shown that small-intestine mucosal enteropathy, accompanied by endotoxemia and a persistent systemic inflammatory response, accounts for up to 64% of the growth faltering in Gambian infants. OBJECTIVE: The objective was to test whether glutamine, with its putative trophic effects on enterocytes, immune cells, and intestinal integrity, can accelerate the repair of the intestine, lower immunostimulation, and reduce growth faltering. DESIGN:Ninety-three infants aged 4-10 mo from the West Kiang region of The Gambia were studied in a double-blind, double-placebo, controlled trial. Glutamine (0.25 mg/kg body wt) or a placebo that contained an isonitrogenous, isoenergetic mix of nonessential amino acids was orally administered twice daily throughout the 5-mo rainy season. Anthropometric measurements were made monthly during the supplementation period and for 6 mo after supplementation. Intestinal permeability was measured monthly (by determining the ratio of lactulose to mannitol), and finger-prick blood samples were collected for the analysis of plasma proteins on 3 occasions. RESULTS: Gambian infants showed a seasonal deterioration in growth and persistently elevated acute phase protein concentrations and intestinal permeability. Oral supplementation with glutamine did not improve growth (x +/- SE: weight gain, 60 +/- 19 and 69 +/- 20 g/mo; length gain, 1.01 +/- 0.05 and 0.95 +/- 0.03 cm/mo) or intestinal permeability [lactulose:mannitol ratio: 0.29 (95% CI: 0.23, 0.35) and 0.26 (95% CI: 0.21, 0.32)] in the glutamine and placebo groups, respectively. It also had no effect on infant morbidity or on plasma concentrations of immunoglobulins or acute phase proteins. CONCLUSION:Glutamine supplementation failed to improve growth or intestinal status in malnourished Gambian infants.
RCT Entities:
BACKGROUND: Growth faltering during infancy is a characteristic of life in developing countries. Previous studies have shown that small-intestine mucosal enteropathy, accompanied by endotoxemia and a persistent systemic inflammatory response, accounts for up to 64% of the growth faltering in Gambian infants. OBJECTIVE: The objective was to test whether glutamine, with its putative trophic effects on enterocytes, immune cells, and intestinal integrity, can accelerate the repair of the intestine, lower immunostimulation, and reduce growth faltering. DESIGN: Ninety-three infants aged 4-10 mo from the West Kiang region of The Gambia were studied in a double-blind, double-placebo, controlled trial. Glutamine (0.25 mg/kg body wt) or a placebo that contained an isonitrogenous, isoenergetic mix of nonessential amino acids was orally administered twice daily throughout the 5-mo rainy season. Anthropometric measurements were made monthly during the supplementation period and for 6 mo after supplementation. Intestinal permeability was measured monthly (by determining the ratio of lactulose to mannitol), and finger-prick blood samples were collected for the analysis of plasma proteins on 3 occasions. RESULTS: Gambian infants showed a seasonal deterioration in growth and persistently elevated acute phase protein concentrations and intestinal permeability. Oral supplementation with glutamine did not improve growth (x +/- SE: weight gain, 60 +/- 19 and 69 +/- 20 g/mo; length gain, 1.01 +/- 0.05 and 0.95 +/- 0.03 cm/mo) or intestinal permeability [lactulose:mannitol ratio: 0.29 (95% CI: 0.23, 0.35) and 0.26 (95% CI: 0.21, 0.32)] in the glutamine and placebo groups, respectively. It also had no effect on infant morbidity or on plasma concentrations of immunoglobulins or acute phase proteins. CONCLUSION:Glutamine supplementation failed to improve growth or intestinal status in malnourished Gambian infants.
Authors: Priscilla M Ueno; Reinaldo B Oriá; Elizabeth A Maier; Marjorie Guedes; Orleancio G de Azevedo; David Wu; Tara Willson; Simon P Hogan; Aldo A M Lima; Richard L Guerrant; D Brent Polk; Lee A Denson; Sean R Moore Journal: Am J Physiol Gastrointest Liver Physiol Date: 2011-07-28 Impact factor: 4.052
Authors: Benjamin F Arnold; Clair Null; Stephen P Luby; Leanne Unicomb; Christine P Stewart; Kathryn G Dewey; Tahmeed Ahmed; Sania Ashraf; Garret Christensen; Thomas Clasen; Holly N Dentz; Lia C H Fernald; Rashidul Haque; Alan E Hubbard; Patricia Kariger; Elli Leontsini; Audrie Lin; Sammy M Njenga; Amy J Pickering; Pavani K Ram; Fahmida Tofail; Peter J Winch; John M Colford Journal: BMJ Open Date: 2013-08-30 Impact factor: 2.692
Authors: W A Faubion; M Camilleri; J A Murray; P Kelly; B Amadi; M N Kosek; F Enders; J Larson; G Boe; R Dyer; R Singh Journal: BMJ Glob Health Date: 2016-07-04
Authors: Liandré F van der Merwe; Sophie E Moore; Anthony J Fulford; Katherine E Halliday; Saikou Drammeh; Stephen Young; Andrew M Prentice Journal: Am J Clin Nutr Date: 2012-12-05 Impact factor: 7.045
Authors: John Louis-Auguste; Stephen Greenwald; Michelo Simuyandi; Rose Soko; Rose Banda; Paul Kelly Journal: BMC Gastroenterol Date: 2014-01-15 Impact factor: 3.067
Authors: Richard B Dorshow; Carla Hall-Moore; Nurmohammad Shaikh; Michael R Talcott; William A Faubion; Thomas E Rogers; Jeng Jong Shieh; Martin P Debreczeny; James R Johnson; Roy B Dyer; Ravinder J Singh; Phillip I Tarr Journal: Sci Rep Date: 2017-09-07 Impact factor: 4.379